Affimed Announces Publication of Final Study Results of its Innate Cell Engager Candidate AFM13 in Combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in Blood

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Daniel Sontupe
Market Access

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Matthew Durham
Omnidynamic Marketing

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

David Linetsky
Point-of-Care Marketing

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy